Table 1 Full data of all patients (AR group) and controls (control group)
From: Bone biopsies guided by augmented reality: a pilot study
Gender | Age (y) | Location | CT passes | Dose (mGy*cm) | Duration (min) | Pathology report |
|---|---|---|---|---|---|---|
AR group | ||||||
F | 52 | Pelvis | 4 | 605.43 | 33 | Negative for cancer |
F | 56 | L3 | 4 | 946.00 | 19 | Spondylodiscitis |
M | 80 | Pelvis | 6 | 773.43 | 22 | Metastasis |
M | 67 | L1 | 6 | 326.35 | 21 | Metastasis |
F | 75 | Scapula | 4 | 775.00 | 22 | Multiple myeloma |
F | 83 | Pelvis | 4 | 1427.50 | 23 | Metastasis |
M | 19 | Pelvis | 4 | 912.46 | 17 | Chordoma |
M | 28 | Pelvis | 7 | 2504.00 | 21 | Hemangioma |
Control group | ||||||
M | 61 | Pelvis | 8 | 1927.00 | 18 | Metastasis |
F | 39 | L1 | 8 | 1089.00 | 20 | Hemangioma |
F | 74 | Pelvis | 7 | 1531.00 | 20 | Osteoblastoma |
M | 35 | L2 | 7 | 919.00 | 17 | Spondylodiscitis |
F | 63 | Scapula | 11 | 2287.00 | 25 | Chondrosarcoma |
M | 64 | Pelvis | 12 | 2068.00 | 27 | Multiple myeloma |
F | 69 | Pelvis | 10 | 1686.00 | 26 | Metastasis |
M | 74 | Pelvis | 14 | 4125.00 | 32 | ARMD |